Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 31, 2025
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
GlobeNewswire
·
March 31, 2025
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at the AACR Annual Meeting highlight the …
Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum
GlobeNewswire
·
March 31, 2025
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter …
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 31, 2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
GlobeNewswire
·
March 31, 2025
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today …
Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results
GlobeNewswire
·
March 31, 2025
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months ended December 31, 2024. Summary of …
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
GlobeNewswire
·
March 31, 2025
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences …
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 31, 2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 …
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
GlobeNewswire
·
March 31, 2025
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS …
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 31, 2025
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, …
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
GlobeNewswire
·
March 31, 2025
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026 …
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewswire
·
March 31, 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People …
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
GlobeNewswire
·
March 31, 2025
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization …
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
GlobeNewswire
·
March 31, 2025
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded …
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
GlobeNewswire
·
March 31, 2025
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics Clinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy (“DMD …
OPEN Health Appoints Matt D’Auria as Chief Executive Officer to Drive Innovation and Growth
GlobeNewswire
·
March 31, 2025
London, March 31, 2025 (GLOBE NEWSWIRE) -- March 31, 2025, London, UK – OPEN Health Group is pleased to announce the appointment of Matt D’Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of experience in …
Glucofreedom Drops Reviews (EXPOSED) Gluco Revive BloodSugar Control ORDER NOW!
GlobeNewswire
·
March 31, 2025
AURORA, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- The maximum number of people are seen to have blood sugar these days. While for many the reason is not caring for their health as it should be, the other reason includes things like wrong food choices. This …
SBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ Expansion
GlobeNewswire
·
March 31, 2025
TOKYO, March 31, 2025 (GLOBE NEWSWIRE) -- Shonan Beauty Clinic, supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical," or the "Company") in management services, today announced the expansion of its multi-brand strategy as part …
AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances
GlobeNewswire
·
March 31, 2025
MILAN, March 31, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company, in collaboration with the Telethon Institute of Genetics and Medicine (TIGEM), announces the publication of their preclinical research in …
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
GlobeNewswire
·
March 31, 2025
PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for …
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
GlobeNewswire
·
March 31, 2025
PARIS et CAMBRIDGE, Mass., 31 mars 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les …